Market closedADR
Inventiva/$IVA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Inventiva
Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Majority of the group's revenue is derived from its research partnerships with AbbVie and BI.
Ticker
$IVA
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
116
Website
Inventiva Metrics
BasicAdvanced
$354M
-
-$3.51
0.99
-
Price and volume
Market cap
$354M
Beta
0.99
52-week high
$4.05
52-week low
$2.67
Average daily volume
18K
Financial strength
Current ratio
0.924
Quick ratio
0.903
Long term debt to equity
-95.626
Total debt to equity
-169.953
Interest coverage (TTM)
-7.88%
Management effectiveness
Return on assets (TTM)
-63.60%
Return on equity (TTM)
265.67%
Valuation
Price to revenue (TTM)
13.573
Price to book
-2.92
Price to tangible book (TTM)
-2.91
Price to free cash flow (TTM)
-2.317
Growth
Revenue change (TTM)
-38.24%
Earnings per share change (TTM)
26.56%
3-year revenue growth (CAGR)
20.09%
3-year earnings per share growth (CAGR)
34.47%
Inventiva News
AllArticlesVideos
Inventiva announces the publication in Clinical Gastroenterology and Hepatology of its analysis of new biomarker signatures predictive of histological response in patients with MASH treated with lanifibranor
GlobeNewsWire·5 days ago
Inventiva announces filing of its 2024 Universal Registration Document and 2024 Annual Report on Form 20-F
GlobeNewsWire·2 weeks ago
Inventiva announces completion of enrollment in the Phase 3 NATiV3 clinical trial of lanifibranor in patients with MASH and advanced fibrosis
GlobeNewsWire·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Inventiva stock?
Inventiva (IVA) has a market cap of $354M as of April 29, 2025.
What is the P/E ratio for Inventiva stock?
The price to earnings (P/E) ratio for Inventiva (IVA) stock is 0 as of April 29, 2025.
Does Inventiva stock pay dividends?
No, Inventiva (IVA) stock does not pay dividends to its shareholders as of April 29, 2025.
When is the next Inventiva dividend payment date?
Inventiva (IVA) stock does not pay dividends to its shareholders.
What is the beta indicator for Inventiva?
Inventiva (IVA) has a beta rating of 0.99. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.